NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy
Open Access
- 1 June 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 189 (5), 982-984
- https://doi.org/10.1111/bjh.16628
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81670121, 81770120)
This publication has 6 references indexed in Scilit:
- NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyBlood Advances, 2019
- Treatment of MDSBlood, 2019
- TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromesBritish Journal of Haematology, 2016
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesThe New England Journal of Medicine, 2016
- Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromesNature Communications, 2015
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) TrialJournal of Clinical Oncology, 2009